Summary:
- The FDA panel has recommended changes to the labels of menopausal hormone therapy (MHT) medications to provide more information about the potential risks and benefits.
- The panel emphasized the importance of educating healthcare providers and patients about the appropriate use of MHT, including the need to individualize treatment based on a woman's specific health status and preferences.
- The panel's recommendations aim to help women make informed decisions about MHT and ensure that the potential risks and benefits are clearly communicated, allowing for a more personalized approach to managing menopausal symptoms.